Arcellx (ACLX) Cash from Investing Activities (2021 - 2025)
Arcellx (ACLX) recorded quarterly Cash from Investing Activities of $57.8 million in Q4 2025, up 388.61% quarter-over-quarter from -$20.0 million in Q3 2025, and up 1502.86% on a YoY basis from $3.6 million in Q4 2024.
Arcellx (ACLX) Cash from Investing Activities (2021 - 2025) Analysis & Trends
Arcellx's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $57.8 million for Q4 2025.
- In Q4 2025, Cash from Investing Activities rose 1502.86% year-over-year to $57.8 million; the TTM figure through Dec 2025 stood at $86.3 million (up 147.15% YoY), while the FY2025 annual figure was $86.3 million, up 147.15% from the prior year.
- Cash from Investing Activities was $57.8 million for Q4 2025 at Arcellx, up from -$20.0 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $57.8 million in Q4 2025 to a low of -$206.8 million in Q1 2024.
- Historically, Cash from Investing Activities has averaged -$22.4 million across 5 years, with a median of -$6.0 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities sank 32807.22% in 2022, then soared 1502.86% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at -$17.7 million in 2021, then jumped by 290.35% to $33.6 million in 2022, then plunged by 37.49% to $21.0 million in 2023, then sank by 119.6% to -$4.1 million in 2024, then surged by 1502.86% to $57.8 million in 2025.
- The last three Cash from Investing Activities figures came in at $57.8 million (Q4 2025), -$20.0 million (Q3 2025), and $10.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 57.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 57.80 Mn |
| Dec 31, 2025 | 57.80 Mn |
| Sep 30, 2025 | -20.03 Mn |
| Sep 30, 2025 | -20.03 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Mar 31, 2025 | 37.78 Mn |
| Mar 31, 2025 | 37.78 Mn |
| Dec 31, 2024 | -4.12 Mn |
| Dec 31, 2024 | -4.12 Mn |
| Sep 30, 2024 | 35.76 Mn |
| Sep 30, 2024 | 35.76 Mn |
| Jun 30, 2024 | -7.87 Mn |
| Jun 30, 2024 | -7.87 Mn |
| Mar 31, 2024 | -206.81 Mn |
| Mar 31, 2024 | -206.81 Mn |
| Dec 31, 2023 | 21.02 Mn |
| Dec 31, 2023 | 21.02 Mn |
| Sep 30, 2023 | -160.03 Mn |
| Sep 30, 2023 | -160.03 Mn |